Navigation Links
Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012
Date:3/1/2012

BOONTON, N.J., March 1, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE), a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company's senior management team will host a conference call and live audio webcast on Thursday, March 8, 2012 at 11 a.m. ET to discuss fourth quarter and full-year 2011 financial results.

Interested participants and investors may access the conference call at 11 a.m. ET by dialing 866-277-1181 (U.S./Canada) or 617-597-5358 (international); participant code 82583482.  An audio webcast can be accessed by logging on to the Investors and Media section under the Events tab of the Unigene web site, http://www.unigene.com.  

A telephonic replay of the call will be available for two weeks beginning at 2 p.m. ET on March 8.  Access numbers for this replay are 888-286-8010 (U.S./Canada) and 617-801-6888 (international); participant code 18902945. The webcast replay will remain available in the Investors section of the Unigene Laboratories web site for 30 days.

About Unigene Laboratories, Inc.

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform.  Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relation
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
2. Unigenes 2011 Year in Review - Key Elements in Place to Address Debt in 2012
3. Unigene to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 13, 2011
4. Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
5. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
6. Updated: Life Technologies Announces Fourth Quarter and Fiscal Year 2011 Results
7. ARUP Laboratories Announces Creation of Business Innovations Division
8. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
9. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
10. Regeneron Announces March 2012 Investor Conference Presentations
11. MiMedx Group Announces 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
(Date:8/26/2014)... Israel , August 26, 2014 ... 3DM, supports NHS hospitals with surgery validation using its Stratasys ... - Performing surgery on 3D printed models prior to ... and provides an effective aid for both patient and surgeon ... SSYS ), a global leader of 3D printing and ...
(Date:8/26/2014)... Aug. 26, 2014 Technology Applications International ... (NUUU) has two (2) wholly- owned subsidiaries, Renuell ... harness scientifically advanced technology to provide advanced solutions ... Renuell Int,l, Inc. is launching its REJUVEL ... products that is made possible because of its ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
Breaking Biology Technology:Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 2Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 3Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 4Twelve UK Hospitals Enjoy Reduced Surgical Procedure Times and Decline in Costs by Implementing Stratasys 3D Printing Solutions 5Technology Applications International Corporation, Trading Symbol NUUU now trading on NASDAQ's Over the Counter Bulletin Board (OTC BB) 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4
... -. Actavis Group, the,international generic pharmaceuticals company, has ... Food & Drug,Administration. Distribution of the product will ... equivalent to Pfizer,s,Camptosar(R) will be available in 40 ... and is,used in the treatment of patients with ...
... CryoCath,s Cryoablation System, SAN DIEGO, Feb. 28 ... focused on the treatment of cardiac,arrhythmias, announced today ... the,United States International Trade Commission (ITC) alleging that ... by infringing on,several CryoCor patents with its cryoablation ...
... Johnson, Jr. Resigns as President and Chief Executive ... Opportunities, HAYWARD, Calif., Feb. 28 Kosan ... Robert G. Johnson, Jr.,M.D., Ph.D., has resigned as ... Kosan,s Board of Directors. Helen S. Kim, who ...
Cached Biology Technology:Actavis Receives Approval for Irinotecan Hydrochloride Injection; Extends US Portfolio with First Injectable Product 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 2CryoCor Requests International Trade Commission Investigation Into CryoCath for Patent Infringement 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 2Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 3Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 4Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 5Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 6Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 7Kosan Announces Senior Management Changes and Clinical Portfolio Priorities 8
(Date:8/27/2014)... have found that century-old museum specimens hold clues to how ... can weaken and kill trees and the news is ... increase on oak and maple trees in warmer urban areas, ... with global warming," says Dr. Elsa Youngsteadt, a research associate ... the work. , "More scale insects would be a problem, ...
(Date:8/26/2014)... pressure from policymakers, consumers, and suppliers has prompted ... reducing the pollutants they emit from their smokestacks ... must also assess environmental performance at every step ... materials to the use and recycling of their ... the discipline known as life cycle engineering, which ...
(Date:8/26/2014)... and social problems such as global warming and ... does the burden fall on our failure as ... a new study in the Journal of ... for solving global problems from governments to consumers ... "When businesses convince politicians to encourage responsible consumption ...
Breaking Biology News(10 mins):Museum specimens, modern cities show how an insect pest will respond to climate change 2Yale journal explores advances in sustainable manufacturing 2An inconvenient truth: Does responsible consumption benefit corporations more than society? 2
... immobile organisms like plants cope when faced with alterations ... in light of new environmental conditions brought on by ... published in the Nov. 16 issue of the journal ... as their maternal plant performed almost 3 times better ...
... million-year-old dinosaur that had a mouth that worked like ... translucent skull bones will be unveiled Thursday, Nov. 15, ... Sahara by National Geographic Explorer-in-Residence Paul Sereno, paleontologist and ... a plant eater known as Nigersaurus taqueti. Originally named ...
... Cancer Foundation today announced they will collectively donate $6 ... Amplification of Research), an innovative research initiative focused on ... to treat prostate cancer, as well as other research ... the first phase of research and development with a ...
Cached Biology News:Evolutionary biology research on plant shows significance of maternal effects 2Dinosaur from Sahara ate like a 'mesozoic cow' 2Dinosaur from Sahara ate like a 'mesozoic cow' 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 2Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 3Safeway Inc. and PCF to fund landmark prostate cancer research collaboration 4
... cm, is used for vertical slab gel electrophoresis ... The cell is supplied without spacers and combs. ... gaskets, lower buffer chamber, lid with cables, 2 ... buffer dam, casting stand with gaskets, leveling bubble, ...
CleanCut agarose is used to prepare genomic DNA plugs for use in pulsed field gel electrophoresis (PFGE) applications. Supplied as a 12 ml solution of 2% agarose....
...
... This system uses the Adept CE 4100 ... CE 4200 dual wavelength detector for ... PowerStream data processing software and interface unit, CE ... Windows XP may also be used with Windows ...
Biology Products: